Long-term outcomes after endoscopic submucosal dissection for differentiated-type early gastric cancer that fulfilled expanded indication criteria: A prospective cohort study.
Endoscopic submucosal dissection
Gastric cancer
Guideline
Survival
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
25
11
2019
revised:
21
06
2020
accepted:
27
06
2020
pubmed:
15
7
2020
medline:
26
8
2021
entrez:
15
7
2020
Statut:
ppublish
Résumé
Endoscopic resection for early gastric cancer (EGC) is widely performed. However, there is still a paucity of strong evidence regarding long-term outcomes after endoscopic submucosal dissection (ESD) for the expanded indication criteria of the Japanese guidelines (ver. 2010). Endoscopic submucosal dissection was performed in patients with EGC that met the expanded indication criteria: (i) cT1a, differentiated-type EGC of 2 to 5 cm, ulcer negative or (ii) cT1a, differentiated-type EGC of ≤3 cm, ulcer positive. Patients whose pathological examination fulfilled the curative resection criteria were then enrolled in this cohort study: negative vertical margin, negative lymphovascular invasion, and (i) pT1a, differentiated-type, and ulcer negative; (ii) pT1a, differentiated-type, ≤3 cm, and ulcer positive; or (iii) pT1b1 (<500-μm submucosal invasion), differentiated-type, and ≤3 cm. Patients with only a positive horizontal margin as a noncurative factor were included for follow-up. From September 2003 to February 2012, a total of 356 patients underwent ESD, and 214 were enrolled in the survival analysis. One hundred twenty patients (56%) had >2 cm in diameter and ulcer-negative lesions, and 94 (44%) had ≤3 cm and ulcer-positive lesions. The vital status at 5 years after ESD was confirmed in all (100%) patients. No local or metastatic recurrence was detected; however, 26 metachronous gastric cancers developed, and 1 patient died of metachronous gastric cancer. The 5-year disease-specific and overall survival rates were 99.5% (95% confidence interval [CI], 97.2%-100%) and 93.9% (95% CI, 89.8%-96.4%), respectively. ESD for EGC that fulfills the expanded criteria is feasible and shows favorable long-term outcomes.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Endoscopic resection for early gastric cancer (EGC) is widely performed. However, there is still a paucity of strong evidence regarding long-term outcomes after endoscopic submucosal dissection (ESD) for the expanded indication criteria of the Japanese guidelines (ver. 2010).
METHODS
METHODS
Endoscopic submucosal dissection was performed in patients with EGC that met the expanded indication criteria: (i) cT1a, differentiated-type EGC of 2 to 5 cm, ulcer negative or (ii) cT1a, differentiated-type EGC of ≤3 cm, ulcer positive. Patients whose pathological examination fulfilled the curative resection criteria were then enrolled in this cohort study: negative vertical margin, negative lymphovascular invasion, and (i) pT1a, differentiated-type, and ulcer negative; (ii) pT1a, differentiated-type, ≤3 cm, and ulcer positive; or (iii) pT1b1 (<500-μm submucosal invasion), differentiated-type, and ≤3 cm. Patients with only a positive horizontal margin as a noncurative factor were included for follow-up.
RESULTS
RESULTS
From September 2003 to February 2012, a total of 356 patients underwent ESD, and 214 were enrolled in the survival analysis. One hundred twenty patients (56%) had >2 cm in diameter and ulcer-negative lesions, and 94 (44%) had ≤3 cm and ulcer-positive lesions. The vital status at 5 years after ESD was confirmed in all (100%) patients. No local or metastatic recurrence was detected; however, 26 metachronous gastric cancers developed, and 1 patient died of metachronous gastric cancer. The 5-year disease-specific and overall survival rates were 99.5% (95% confidence interval [CI], 97.2%-100%) and 93.9% (95% CI, 89.8%-96.4%), respectively.
CONCLUSION
CONCLUSIONS
ESD for EGC that fulfills the expanded criteria is feasible and shows favorable long-term outcomes.
Identifiants
pubmed: 32663347
doi: 10.1111/jgh.15182
pmc: PMC7983953
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
664-670Informations de copyright
© 2020 The Authors. Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Gastric Cancer. 2006;9(2):88-92
pubmed: 16767363
Endoscopy. 2010 Dec;42(12):1112-5
pubmed: 21120780
Gastric Cancer. 2011 Jun;14(2):113-23
pubmed: 21573742
Gastric Cancer. 2016 Jan;19(1):198-205
pubmed: 25616808
Gastrointest Endosc. 2017 Jan;85(1):143-152
pubmed: 27365265
Gastrointest Endosc. 2007 Jul;66(1):186-93
pubmed: 17591498
Gastrointest Endosc. 2011 Sep;74(3):485-93
pubmed: 21741645
Am J Gastroenterol. 2007 Aug;102(8):1610-6
pubmed: 17403076
Endoscopy. 2015 Sep;47(9):784-93
pubmed: 26111362
Gastric Cancer. 2011 Jun;14(2):101-12
pubmed: 21573743
Ann Gastroenterol. 2015 Jan-Mar;28(1):66-71
pubmed: 25608929
J Clin Gastroenterol. 2012 Feb;46(2):124-9
pubmed: 21959325
Gastrointest Endosc. 2016 Oct;84(4):572-86
pubmed: 27345132
Dig Endosc. 2013 Mar;25 Suppl 1:71-8
pubmed: 23368986
Endoscopy. 2009 Nov;41(11):923-8
pubmed: 19802773
Endoscopy. 2015 Dec;47(12):1113-8
pubmed: 26165734
Br J Surg. 2010 Jun;97(6):868-71
pubmed: 20301163
Can J Gastroenterol Hepatol. 2015 Aug-Sep;29(6):321-5
pubmed: 26069891
J Gastroenterol. 2010;45(1):30-6
pubmed: 19760133
Gastrointest Endosc. 2009 Jun;69(7):1228-35
pubmed: 19249769
World J Gastrointest Endosc. 2013 Jun 16;5(6):281-7
pubmed: 23772265
Lancet. 2008 Aug 2;372(9636):392-7
pubmed: 18675689
BMC Surg. 2018 Sep 25;18(1):79
pubmed: 30253755
J Gastroenterol Hepatol. 2010 Dec;25(12):1844-9
pubmed: 21091995
Surg Endosc. 2019 Jan;33(1):26-32
pubmed: 30298447
Gastric Cancer. 2014 Oct;17(4):697-702
pubmed: 24310295
Gastrointest Endosc. 2016 Jun;83(6):1184-1192.e1
pubmed: 26546980
Gastrointest Endosc. 2012 Jun;75(6):1159-65
pubmed: 22482916
Endoscopy. 2018 May;50(5):479-486
pubmed: 29228402
Cancer Sci. 2012 Jun;103(6):1111-20
pubmed: 22364479
Gastroenterology. 2016 May;150(5):1113-1124.e5
pubmed: 26836587
Gastric Cancer. 2000 Dec;3(4):219-225
pubmed: 11984739
Helicobacter. 2014 Aug;19(4):243-8
pubmed: 25056262
Endoscopy. 2013 Sep;45(9):708-13
pubmed: 23918620
Gut. 2013 Oct;62(10):1425-32
pubmed: 22914298
Dig Endosc. 2014 Mar;26(2):183-91
pubmed: 23560494
J Gastroenterol Hepatol. 2021 Mar;36(3):664-670
pubmed: 32663347
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Natl Cancer Inst Monogr. 1961 Sep;6:101-21
pubmed: 13889176
Gastric Cancer. 2018 Jan;21(1):114-123
pubmed: 28224238
Gastric Cancer. 1998 Dec;1(1):10-24
pubmed: 11957040